Peer-reviewed veterinary case report
Treatment results for T cell lymphoma in 70 dogs using VELCAP-TSC
By Goodman, Ingrid H et al.·Published in Veterinary journal (London, England : 1997)·2016·Animal Referral Hospital, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013).
- Species:
- dog
Plain-English summary
A group of 70 dogs with T cell lymphoma, a type of cancer that affects the immune system, was treated with a specific chemotherapy protocol called VELCAP-TSC. About 73% of the dogs went into remission, with 64% achieving complete remission. The dogs that were neutropenic (low white blood cell count) at diagnosis had a better chance of complete remission. While the average survival time was around 237 days, some dogs lived longer than a year, indicating that there are treatment options that can lead to positive outcomes for dogs with this type of lymphoma.
People also search for: dog T cell lymphoma treatment · canine lymphoma survival rates · chemotherapy for dogs with cancer
Abstract
The immunophenotype of canine non-indolent lymphoma has prognostic value; dogs with T cell lymphoma have a poorer response rate and shorter survival times than dogs with B cell lymphoma. This study sought to retrospectively evaluate prognostic factors for complete remission (CR), progression free survival (PFS) and overall survival time (OST) in 70 dogs with T cell lymphoma treated with an alkylator-rich, combination protocol. The overall remission was 72.9%; 45 dogs (64.3%) achieved CR and six (8.6%) achieved partial remission. Dogs that were neutropenic at diagnosis were significantly more likely to achieve CR. The median overall PFS was 175 days; 1, 2 and 3 year PFS were 26.8%, 15.8%, and 12.6%, retrospectively, after commencing chemotherapy. Median PFS was significantly longer for dogs that achieved CR. Median OST was 237 days. The 1, 2 and 3 year survival rates were 31%, 20.2% and 11.5%, retrospectively, after commencing chemotherapy. The median OST was significantly longer for dogs that achieved CR and significantly shorter for Boxers and those in substage b at diagnosis. More than 30% of dogs treated with this protocol survived >1 year, suggesting that favourable outcomes and longer survival are possible for a proportion of dogs with T cell lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27017053/